n-3 fatty acids no benefit for high-risk cardio patients

n-3 fatty acids no benefit for high-risk cardio patients
For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular mortality or morbidity, according to a study published in the May 9 issue of the New England Journal of Medicine.

(HealthDay)—For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular mortality or morbidity, according to a study published in the May 9 issue of the New England Journal of Medicine.

Maria Carla Roncaglioni, Ph.D., from the Istituto di Ricerche Farmacologiche Mario Negri in Milan, and colleagues conducted a double-blind, placebo-controlled trial involving 12,513 patients with multiple or atherosclerotic vascular disease, but without myocardial infarction. Participants were randomized to receive 1 g daily n-3 fatty acids (6,244 participants) or placebo (olive oil; 6,269 participants).

With a median of five years of follow-up, the researchers found that the primary end point (cumulative rate of death, nonfatal , and nonfatal stroke) occurred in 11.8 percent of the cohort, 11.7 percent of whom had received n-3 fatty acids and 11.9 percent of whom had received placebo. Similar results were seen for all secondary end points.

"On the basis of the results, we conclude that there was no significant benefit of n-3 fatty acids in reducing the risk of death from cardiovascular causes or hospital admission for cardiovascular causes," the authors write.

The study was partially funded by Pfizer and Sigma Tau.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Fatty acids don't reduce atrial fibrillation recurrence

Dec 21, 2012

(HealthDay)—Polyunsaturated fatty acids (n-3 PUFA) do not reduce the recurrence of atrial fibrillation (AF), according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

Retinopathy severity linked to cardiovascular outcome

Jan 25, 2013

(HealthDay)—For individuals with type 2 diabetes, incident cardiovascular outcomes are determined not only by the severity of diabetic retinopathy but also by its progression, according to research published ...

Recommended for you

Gene variant raises risk for aortic tear and rupture

Apr 17, 2014

Researchers from Yale School of Medicine and Celera Diagnostics have confirmed the significance of a genetic variant that substantially increases the risk of a frequently fatal thoracic aortic dissection or full rupture. ...

Considerable variation in CT use in ischemic stroke

Apr 17, 2014

(HealthDay)—For patients with ischemic stroke there is considerable variation in the rates of high-intensity computed tomography (CT) use, according to a study published online April 8 in Circulation: Ca ...

Beating the clock for ischemic stroke sufferers

Apr 17, 2014

A ground-breaking computer technology raises hope for people struck by ischemic stroke, which is a very common kind of stroke accounting for over 80 per cent of overall stroke cases. Developed by research experts at The Hong ...

User comments